PET Imaging of Brain Tumors

The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer Treatment and Research 2008, Vol.143, p.67-92
1. Verfasser: Fischman, Alan J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 92
container_issue
container_start_page 67
container_title Cancer Treatment and Research
container_volume 143
creator Fischman, Alan J.
description The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the prognosis for patients with primary brain tumors remains very poor; age-adjusted five-year survival is 30.8 percent. Primary brain tumor is the most prevalent solid tumor in children, and patients 19 years old or younger have a five-year survival of 65 percent. Patients aged 44 or younger have a five-year survival of 58.7 percent. In the elderly, prognosis is extremely poor with a five-year survival of less than 6.5 percent in patients aged 65 and older [1]. The epidemiology of primary brain tumors is extremely complex and includes lesions with both benign and malignant histologies. Between 1985 and 1992, over 60,000 patients diagnosed with primary brain tumors were reported to the National Cancer Data Base (NCDB) [2], and in this group the most frequent tumors were glioblastoma multiforme (GBM) and astrocytoma. The World Health Organization (WHO) has established a four-level classification system (Grade I to IV) with Grade I being most benign, and Grade IV most malignant. The most malignant tumors - astrocytomas and GBM (Grade III to IV) - had overall 30 percent and two percent five-year survival in the NCDB series [2].
doi_str_mv 10.1007/978-0-387-75587-8_3
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_21242928</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21242928</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2473-58c3fa084fc22435ff55246332f5d65f089757d0a6023e1670a4e22f66fa95393</originalsourceid><addsrcrecordid>eNo1kE1PwzAMhoMAwTb2CyahnrgFHOf7CNOASZPgMM5R1iVTYW1HQw_8e8I-Lrb8-pElP4RMGNwzAP1gtaFAudFUS5mrcfyMjHMKOdtH5pwMT4NiF2QAFjXlIPCaDFP6BJAaNb8i1yzvLTIxIJP32bKY135TNZuijcVT56umWPZ126Ubchn9NoXxsY_Ix_NsOX2li7eX-fRxQUsUmlNpSh49GBFLRMFljFKiUJxjlGslIxirpV6DV4A8MKXBi4AYlYreSm75iNwd7u669rsP6cfVVSrDduub0PbJIUOBFk0Gb49gv6rD2u26qvbdrzu9kwF2AFJeNZvQuVXbfiXHwP07dNmWA5cVub0wlx3yP4cHWvo</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21242928</pqid></control><display><type>article</type><title>PET Imaging of Brain Tumors</title><source>MEDLINE</source><source>Springer Books</source><creator>Fischman, Alan J.</creator><contributor>Blake, Michael A. ; Kalra, Mannudeep K.</contributor><creatorcontrib>Fischman, Alan J. ; Blake, Michael A. ; Kalra, Mannudeep K.</creatorcontrib><description>The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the prognosis for patients with primary brain tumors remains very poor; age-adjusted five-year survival is 30.8 percent. Primary brain tumor is the most prevalent solid tumor in children, and patients 19 years old or younger have a five-year survival of 65 percent. Patients aged 44 or younger have a five-year survival of 58.7 percent. In the elderly, prognosis is extremely poor with a five-year survival of less than 6.5 percent in patients aged 65 and older [1]. The epidemiology of primary brain tumors is extremely complex and includes lesions with both benign and malignant histologies. Between 1985 and 1992, over 60,000 patients diagnosed with primary brain tumors were reported to the National Cancer Data Base (NCDB) [2], and in this group the most frequent tumors were glioblastoma multiforme (GBM) and astrocytoma. The World Health Organization (WHO) has established a four-level classification system (Grade I to IV) with Grade I being most benign, and Grade IV most malignant. The most malignant tumors - astrocytomas and GBM (Grade III to IV) - had overall 30 percent and two percent five-year survival in the NCDB series [2].</description><identifier>ISSN: 0927-3042</identifier><identifier>ISBN: 0387755861</identifier><identifier>ISBN: 9780387755861</identifier><identifier>EISBN: 9780387755878</identifier><identifier>EISBN: 038775587X</identifier><identifier>DOI: 10.1007/978-0-387-75587-8_3</identifier><identifier>PMID: 18619214</identifier><language>eng</language><publisher>Boston, MA: Springer US</publisher><subject>Biopsy ; Brain - pathology ; Brain Neoplasms - diagnosis ; Brain Neoplasms - pathology ; Cell Proliferation ; Diagnostic Imaging - methods ; Dihydroxyphenylalanine - analogs &amp; derivatives ; Dihydroxyphenylalanine - pharmacology ; Fluorodeoxyglucose F18 - pharmacology ; Humans ; Lipids - chemistry ; Medical Oncology - methods ; Methionine - pharmacology ; Positron-Emission Tomography - methods ; Radiopharmaceuticals - pharmacology ; Tyrosine - analogs &amp; derivatives ; Tyrosine - pharmacology</subject><ispartof>Cancer Treatment and Research, 2008, Vol.143, p.67-92</ispartof><rights>Springer Science+Business Media, LLC 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c2473-58c3fa084fc22435ff55246332f5d65f089757d0a6023e1670a4e22f66fa95393</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/978-0-387-75587-8_3$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/978-0-387-75587-8_3$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,779,780,784,793,27924,27925,38255,41442,42511</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18619214$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Blake, Michael A.</contributor><contributor>Kalra, Mannudeep K.</contributor><creatorcontrib>Fischman, Alan J.</creatorcontrib><title>PET Imaging of Brain Tumors</title><title>Cancer Treatment and Research</title><addtitle>Cancer Treat Res</addtitle><description>The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the prognosis for patients with primary brain tumors remains very poor; age-adjusted five-year survival is 30.8 percent. Primary brain tumor is the most prevalent solid tumor in children, and patients 19 years old or younger have a five-year survival of 65 percent. Patients aged 44 or younger have a five-year survival of 58.7 percent. In the elderly, prognosis is extremely poor with a five-year survival of less than 6.5 percent in patients aged 65 and older [1]. The epidemiology of primary brain tumors is extremely complex and includes lesions with both benign and malignant histologies. Between 1985 and 1992, over 60,000 patients diagnosed with primary brain tumors were reported to the National Cancer Data Base (NCDB) [2], and in this group the most frequent tumors were glioblastoma multiforme (GBM) and astrocytoma. The World Health Organization (WHO) has established a four-level classification system (Grade I to IV) with Grade I being most benign, and Grade IV most malignant. The most malignant tumors - astrocytomas and GBM (Grade III to IV) - had overall 30 percent and two percent five-year survival in the NCDB series [2].</description><subject>Biopsy</subject><subject>Brain - pathology</subject><subject>Brain Neoplasms - diagnosis</subject><subject>Brain Neoplasms - pathology</subject><subject>Cell Proliferation</subject><subject>Diagnostic Imaging - methods</subject><subject>Dihydroxyphenylalanine - analogs &amp; derivatives</subject><subject>Dihydroxyphenylalanine - pharmacology</subject><subject>Fluorodeoxyglucose F18 - pharmacology</subject><subject>Humans</subject><subject>Lipids - chemistry</subject><subject>Medical Oncology - methods</subject><subject>Methionine - pharmacology</subject><subject>Positron-Emission Tomography - methods</subject><subject>Radiopharmaceuticals - pharmacology</subject><subject>Tyrosine - analogs &amp; derivatives</subject><subject>Tyrosine - pharmacology</subject><issn>0927-3042</issn><isbn>0387755861</isbn><isbn>9780387755861</isbn><isbn>9780387755878</isbn><isbn>038775587X</isbn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1PwzAMhoMAwTb2CyahnrgFHOf7CNOASZPgMM5R1iVTYW1HQw_8e8I-Lrb8-pElP4RMGNwzAP1gtaFAudFUS5mrcfyMjHMKOdtH5pwMT4NiF2QAFjXlIPCaDFP6BJAaNb8i1yzvLTIxIJP32bKY135TNZuijcVT56umWPZ126Ubchn9NoXxsY_Ix_NsOX2li7eX-fRxQUsUmlNpSh49GBFLRMFljFKiUJxjlGslIxirpV6DV4A8MKXBi4AYlYreSm75iNwd7u669rsP6cfVVSrDduub0PbJIUOBFk0Gb49gv6rD2u26qvbdrzu9kwF2AFJeNZvQuVXbfiXHwP07dNmWA5cVub0wlx3yP4cHWvo</recordid><startdate>2008</startdate><enddate>2008</enddate><creator>Fischman, Alan J.</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7QO</scope><scope>7TK</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>2008</creationdate><title>PET Imaging of Brain Tumors</title><author>Fischman, Alan J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2473-58c3fa084fc22435ff55246332f5d65f089757d0a6023e1670a4e22f66fa95393</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Biopsy</topic><topic>Brain - pathology</topic><topic>Brain Neoplasms - diagnosis</topic><topic>Brain Neoplasms - pathology</topic><topic>Cell Proliferation</topic><topic>Diagnostic Imaging - methods</topic><topic>Dihydroxyphenylalanine - analogs &amp; derivatives</topic><topic>Dihydroxyphenylalanine - pharmacology</topic><topic>Fluorodeoxyglucose F18 - pharmacology</topic><topic>Humans</topic><topic>Lipids - chemistry</topic><topic>Medical Oncology - methods</topic><topic>Methionine - pharmacology</topic><topic>Positron-Emission Tomography - methods</topic><topic>Radiopharmaceuticals - pharmacology</topic><topic>Tyrosine - analogs &amp; derivatives</topic><topic>Tyrosine - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fischman, Alan J.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Cancer Treatment and Research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fischman, Alan J.</au><au>Blake, Michael A.</au><au>Kalra, Mannudeep K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>PET Imaging of Brain Tumors</atitle><jtitle>Cancer Treatment and Research</jtitle><addtitle>Cancer Treat Res</addtitle><date>2008</date><risdate>2008</risdate><volume>143</volume><spage>67</spage><epage>92</epage><pages>67-92</pages><issn>0927-3042</issn><isbn>0387755861</isbn><isbn>9780387755861</isbn><eisbn>9780387755878</eisbn><eisbn>038775587X</eisbn><abstract>The incidence of primary brain tumors is ~ 11:100,000 of the population. In the year 2006, ~ 18,820 new cases of brain and other nervous system tumors were diagnosed in the United States [1] and these tumors were the cause of death in ~ 12,820 patients. Despite advances in diagnosis and therapy, the prognosis for patients with primary brain tumors remains very poor; age-adjusted five-year survival is 30.8 percent. Primary brain tumor is the most prevalent solid tumor in children, and patients 19 years old or younger have a five-year survival of 65 percent. Patients aged 44 or younger have a five-year survival of 58.7 percent. In the elderly, prognosis is extremely poor with a five-year survival of less than 6.5 percent in patients aged 65 and older [1]. The epidemiology of primary brain tumors is extremely complex and includes lesions with both benign and malignant histologies. Between 1985 and 1992, over 60,000 patients diagnosed with primary brain tumors were reported to the National Cancer Data Base (NCDB) [2], and in this group the most frequent tumors were glioblastoma multiforme (GBM) and astrocytoma. The World Health Organization (WHO) has established a four-level classification system (Grade I to IV) with Grade I being most benign, and Grade IV most malignant. The most malignant tumors - astrocytomas and GBM (Grade III to IV) - had overall 30 percent and two percent five-year survival in the NCDB series [2].</abstract><cop>Boston, MA</cop><pub>Springer US</pub><pmid>18619214</pmid><doi>10.1007/978-0-387-75587-8_3</doi><tpages>26</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0927-3042
ispartof Cancer Treatment and Research, 2008, Vol.143, p.67-92
issn 0927-3042
language eng
recordid cdi_proquest_miscellaneous_21242928
source MEDLINE; Springer Books
subjects Biopsy
Brain - pathology
Brain Neoplasms - diagnosis
Brain Neoplasms - pathology
Cell Proliferation
Diagnostic Imaging - methods
Dihydroxyphenylalanine - analogs & derivatives
Dihydroxyphenylalanine - pharmacology
Fluorodeoxyglucose F18 - pharmacology
Humans
Lipids - chemistry
Medical Oncology - methods
Methionine - pharmacology
Positron-Emission Tomography - methods
Radiopharmaceuticals - pharmacology
Tyrosine - analogs & derivatives
Tyrosine - pharmacology
title PET Imaging of Brain Tumors
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T05%3A46%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=PET%20Imaging%20of%20Brain%20Tumors&rft.jtitle=Cancer%20Treatment%20and%20Research&rft.au=Fischman,%20Alan%20J.&rft.date=2008&rft.volume=143&rft.spage=67&rft.epage=92&rft.pages=67-92&rft.issn=0927-3042&rft.isbn=0387755861&rft.isbn_list=9780387755861&rft_id=info:doi/10.1007/978-0-387-75587-8_3&rft_dat=%3Cproquest_pubme%3E21242928%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&rft.eisbn=9780387755878&rft.eisbn_list=038775587X&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21242928&rft_id=info:pmid/18619214&rfr_iscdi=true